SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Cardiovascular Pharmacology and Therapeutics
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Ford, W. R.
Right arrow Articles by Jugdutt, B. I.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Ford, W. R.
Right arrow Articles by Jugdutt, B. I.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

Characterization of Cardioprotection Mediated by AT2 Receptor Antagonism After Ischemia-Reperfusion in Isolated Working Rat Hearts

William R. Ford

Cardiology Division of the Department of Medicine, University of Alberta

Alexander S. Clanachan

Department of Pharmacology, University of Alberta. Edmonton, Alberta, Canada

Bodh I. Jugdutt

Cardiology Division of the Department of Medicine, University of Alberta

Background: Whether cardioprotection induced by the angiotensin II (AngII) type 2 receptor (AT 2R) antagonist PD123,319 (PD) after ischemia-reperfusion (IR) is influenced by the concentration of PD, presence of AngII, timing of exposure, or inhibition of proton produc tion from glucose metabolism is not known.

Methods and Results: We examined these factors in isolated working rat hearts subjected to IR injury, no treatment (control), or treatment with N6-cyclohexyl adenosine (CHA, 0.5 µmol/L), an adenosine A1 receptor agonist that induces cardioprotection by decreasing pro tons ("positive" control). Compared with control, 1 µmol/L PD present throughout IR im proved recovery of left ventricular work (73 ± 5 vs. 40 ± 8%) to the level with CHA (82 ± 5%), but 0.1 µmol/L PD did not (58 ± 6 vs. 40 ± 8%). AngII (1 nmol/L) did not effect postischemic recovery associated with 1 µmol/L PD (73 ± 7%) but improved that associated with 0.1 µmol/L PD (86 ± 3%). PD (1 µmol/L), present solely during reperfusion, enhanced postischemic left ventricular recovery to 72 ± 5%. Also, PD (1 µmol/L) did not affect glycolytic rates or proton production in nonischemic or IR hearts.

Conclusion: PD-induced cardioprotection is 1) PD concentration-dependent, 2) AngII- sensitive, 3) mediated during reperfusion, and 4) independent of proton production, suggest ing that reduction in IR injury and indirect AT 1R stimulation might be involved.

Key Words: angiotensin • receptor • ischemia-reperfusion • myocardium.

Journal of Cardiovascular Pharmacology and Therapeutics, Vol. 5, No. 3, 211-221 (2000)
DOI: 10.1054/JCPT.2000.7451


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement